FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name ar	2. Issuer Name and Ticker or Trading Symbol SPECTRUM PHARMACEUTICALS INC [SPPI]										tionship of Reporting all applicable) Director		10%	Person(s) to Issuer 10% Owner Other (specify below)				
(Last) (First) (Middle) 11500 S. EASTERN AVE., SUITE 240						3. Date of Earliest Transaction (Month/Day/Year) 05/14/2018										Offic belo	er (give title w)	
(Street) HENDER			9052 Zip)		4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									dual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/Y				Year) if	Execution Date,			3. Transac Code (In 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			4 and Secu Bene Own		ficially d	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
									Code	v	Amount	(A) c			Following (I Reported Transaction(s) (Instr. 3 and 4)		(11301. 4)	(1134. 4)
Common Stock, \$0.001 par value 05/14/20						18			S		9,275	D \$18.32		32(1)	28,850(2)		D	
		Та	ble l	l - Derivat (e.g., pı							osed of, convertib				ned			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		Execu	eemed ution Date, / th/Day/Year)		saction le (Instr. and Instruction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		rative rities ired r osed) . 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form: Direct (D or Indire (I) (Instr. 4)	Beneficial Ownership

Explanation of Responses:

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.20 to \$18.462, inclusive. The reporting person undertakes to provide to Spectrum Pharmaceuticals, Inc., any security holder of Spectrum Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- 2. Since the date of the reporting person's last ownership report, he transferred 5,000 shares of the Company's common stock and a non-qualified director stock option to purchase 10,000 shares of fully-vested shares of the Company's common stock to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife.

Remarks:

/s/ Kurt A. Gustafson, attorney-in-fact for Raymond <u>05/15/2018</u> W. Cohen

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.